Hyperfine 2025 Q3 Earnings Sequential Revenue Growth Amid Widening Net Loss

Hyperfine(HYPR) reported fiscal 2025 Q3 earnings on Nov 14th, 2025. The stock price surged 12.75% in the latest trading day but declined 47.73% month-to-date.

Hyperfine’s Q3 2025 earnings report revealed a 5.7% year-over-year revenue decline to $3.44 million, missing the $3.46 million consensus. However, the company raised its Q4 2025 revenue guidance to $5–6 million, reflecting a 60% sequential and 137% year-over-year growth at the midpoint. The stable EPS of -$0.14 contrasted with a widened net loss of $11.02 million, a 6.7% increase from Q3 2024. Management emphasized sequential revenue growth and improved gross margins as positive indicators for future performance.

Revenue

Device sales accounted for the majority of the revenue at $2.89 million, while service revenue contributed $546,000. Total sales for the quarter amounted to $3.44 million, reflecting a 5.7% decrease from the $3.64 million recorded in the same period last year.

Earnings/Net Income

Hyperfine maintained stable EPS at -$0.14 in Q3 2025 compared to Q3 2024. Meanwhile, the company’s net loss widened to -$11.02 million, a 6.7% increase from the -$10.33 million loss in Q3 2024. The sustained losses over five years highlight ongoing financial challenges. Despite stable EPS, the net loss widened by 6.7%, underscoring the need for operational improvements.

Post-Earnings Price Action Review

The stock price of Hyperfine surged 12.75% during the latest trading day, climbed 7.48% during the most recent full trading week, and plummeted 47.73% month-to-date. The volatile price action reflects mixed investor sentiment following the earnings report.

CEO Commentary

Maria Sainz highlighted Q3 2025 revenue of $3.4M, a 27% sequential growth, and a record 54% gross margin driven by the next-generation Swoop system and Opti AI software. She emphasized strategic priorities, including hospital, office, and international market expansion, supported by a $20M capital raise.

Guidance

Brett Hale provided Q4 2025 revenue guidance of $5–6M (60% sequential, 137% YoY growth at midpoint) and full-year 2025 revenue of $13–14M. Gross margins are projected to expand to 49–51% YoY, with >50% margins anticipated at scale.

Additional News

1. Norway’s First Swoop Installation: Stavanger University Hospital became the first in Norway to install Hyperfine’s Swoop® system, marking a milestone in accessible point-of-care brain imaging.

2. $20M Capital Raise: Hyperfine secured $20.1M in October, extending its cash runway to mid-2027 and supporting commercial expansion.

3. Regulatory Approvals: Opti AI software received CE Mark and UKCA approval, enabling global deployment in Q4 2025.

Financial Performance

The company’s Q3 2025 net loss of $11.02 million, a 6.7% increase from Q3 2024, reflects ongoing operational challenges. Despite a 27% sequential revenue growth, the year-over-year decline of 5.7% underscores market headwinds. Management’s guidance for Q4 2025, however, signals confidence in the Swoop system’s adoption and operational leverage.

Strategic Outlook

Hyperfine’s focus on hospital, office, and international markets, coupled with regulatory progress and capital infusion, positions the company to scale revenue through diversified verticals. The CEO’s emphasis on breakeven timelines and international expansion highlights long-term growth potential.